Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma

The Italian experience and results of its use in daily clinical practice outside clinical trials

Pier Luigi Zinzani, Simonetta Viviani, Antonella Anastasia, Umberto Vitolo, Stefano Luminari, Francesco Zaja, Paolo Corradini, Michele Spina, Ercole Brusamolino, Alessandro M. Gianni, Armando Santoro, Barbara Botto, Enrico Derenzini, Cinzia Pellegrini, Lisa Argnani

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Clinical trial results indicate that brentuximab vedotin brings considerable promise for the treatment of patients with relapsed or refractory Hodgkin's lymphoma. A retrospective multicenter study was conducted on 65 heavily pretreated patients who underwent therapy through a Named Patient Program in Italy (non trial-setting). The primary study endpoint was the objective response rate; secondary endpoints were safety, overall survival and progression- free survival. The best overall response rate (70.7%), including 21.5% complete responses, was observed at the first restaging after the third cycle of treatment. After a median follow up of 13.2 months, the overall survival rate at 20 months was 73.8% while the progression-free survival rate at 20 months was 24.2%. Globally nine patients are in continuous complete response with a median follow up of 14 months (range, 10-19 months). Four patients proceeded to autotransplantation and nine to allotransplantation. The most frequent extra-hematologic toxicity was peripheral neuropathy, observed in 21.5% of cases (9 patients with grade 1/2 and 5 patients with grade 3/4); neurological toxicity led to discontinuation of treatment in three patients and to dose reduction in four. In general the treatment was well tolerated and toxicities, both hematologic and extra-hematologic, were manageable. This report indicates and confirms that brentuximab vedotin as a single agent is effective and safe also when used in standard, everyday clinical practice outside a clinical trial. Best overall responses were recorded after three or four cycles and showed that brentuximab vedotin provides an effective bridge to further therapeutic interventions.

Original languageEnglish
Pages (from-to)1232-1236
Number of pages5
JournalHaematologica
Volume98
Issue number8
DOIs
Publication statusPublished - Aug 1 2013

Fingerprint

Hodgkin Disease
Clinical Trials
Disease-Free Survival
Therapeutics
Survival Rate
cAC10-vcMMAE
Autologous Transplantation
Peripheral Nervous System Diseases
Italy
Multicenter Studies
Retrospective Studies
Safety
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma : The Italian experience and results of its use in daily clinical practice outside clinical trials. / Zinzani, Pier Luigi; Viviani, Simonetta; Anastasia, Antonella; Vitolo, Umberto; Luminari, Stefano; Zaja, Francesco; Corradini, Paolo; Spina, Michele; Brusamolino, Ercole; Gianni, Alessandro M.; Santoro, Armando; Botto, Barbara; Derenzini, Enrico; Pellegrini, Cinzia; Argnani, Lisa.

In: Haematologica, Vol. 98, No. 8, 01.08.2013, p. 1232-1236.

Research output: Contribution to journalArticle

Zinzani, PL, Viviani, S, Anastasia, A, Vitolo, U, Luminari, S, Zaja, F, Corradini, P, Spina, M, Brusamolino, E, Gianni, AM, Santoro, A, Botto, B, Derenzini, E, Pellegrini, C & Argnani, L 2013, 'Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: The Italian experience and results of its use in daily clinical practice outside clinical trials', Haematologica, vol. 98, no. 8, pp. 1232-1236. https://doi.org/10.3324/haematol.2012.083048
Zinzani, Pier Luigi ; Viviani, Simonetta ; Anastasia, Antonella ; Vitolo, Umberto ; Luminari, Stefano ; Zaja, Francesco ; Corradini, Paolo ; Spina, Michele ; Brusamolino, Ercole ; Gianni, Alessandro M. ; Santoro, Armando ; Botto, Barbara ; Derenzini, Enrico ; Pellegrini, Cinzia ; Argnani, Lisa. / Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma : The Italian experience and results of its use in daily clinical practice outside clinical trials. In: Haematologica. 2013 ; Vol. 98, No. 8. pp. 1232-1236.
@article{41540f347a6a4b5583232aadd7b632a7,
title = "Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: The Italian experience and results of its use in daily clinical practice outside clinical trials",
abstract = "Clinical trial results indicate that brentuximab vedotin brings considerable promise for the treatment of patients with relapsed or refractory Hodgkin's lymphoma. A retrospective multicenter study was conducted on 65 heavily pretreated patients who underwent therapy through a Named Patient Program in Italy (non trial-setting). The primary study endpoint was the objective response rate; secondary endpoints were safety, overall survival and progression- free survival. The best overall response rate (70.7{\%}), including 21.5{\%} complete responses, was observed at the first restaging after the third cycle of treatment. After a median follow up of 13.2 months, the overall survival rate at 20 months was 73.8{\%} while the progression-free survival rate at 20 months was 24.2{\%}. Globally nine patients are in continuous complete response with a median follow up of 14 months (range, 10-19 months). Four patients proceeded to autotransplantation and nine to allotransplantation. The most frequent extra-hematologic toxicity was peripheral neuropathy, observed in 21.5{\%} of cases (9 patients with grade 1/2 and 5 patients with grade 3/4); neurological toxicity led to discontinuation of treatment in three patients and to dose reduction in four. In general the treatment was well tolerated and toxicities, both hematologic and extra-hematologic, were manageable. This report indicates and confirms that brentuximab vedotin as a single agent is effective and safe also when used in standard, everyday clinical practice outside a clinical trial. Best overall responses were recorded after three or four cycles and showed that brentuximab vedotin provides an effective bridge to further therapeutic interventions.",
author = "Zinzani, {Pier Luigi} and Simonetta Viviani and Antonella Anastasia and Umberto Vitolo and Stefano Luminari and Francesco Zaja and Paolo Corradini and Michele Spina and Ercole Brusamolino and Gianni, {Alessandro M.} and Armando Santoro and Barbara Botto and Enrico Derenzini and Cinzia Pellegrini and Lisa Argnani",
year = "2013",
month = "8",
day = "1",
doi = "10.3324/haematol.2012.083048",
language = "English",
volume = "98",
pages = "1232--1236",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma

T2 - The Italian experience and results of its use in daily clinical practice outside clinical trials

AU - Zinzani, Pier Luigi

AU - Viviani, Simonetta

AU - Anastasia, Antonella

AU - Vitolo, Umberto

AU - Luminari, Stefano

AU - Zaja, Francesco

AU - Corradini, Paolo

AU - Spina, Michele

AU - Brusamolino, Ercole

AU - Gianni, Alessandro M.

AU - Santoro, Armando

AU - Botto, Barbara

AU - Derenzini, Enrico

AU - Pellegrini, Cinzia

AU - Argnani, Lisa

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Clinical trial results indicate that brentuximab vedotin brings considerable promise for the treatment of patients with relapsed or refractory Hodgkin's lymphoma. A retrospective multicenter study was conducted on 65 heavily pretreated patients who underwent therapy through a Named Patient Program in Italy (non trial-setting). The primary study endpoint was the objective response rate; secondary endpoints were safety, overall survival and progression- free survival. The best overall response rate (70.7%), including 21.5% complete responses, was observed at the first restaging after the third cycle of treatment. After a median follow up of 13.2 months, the overall survival rate at 20 months was 73.8% while the progression-free survival rate at 20 months was 24.2%. Globally nine patients are in continuous complete response with a median follow up of 14 months (range, 10-19 months). Four patients proceeded to autotransplantation and nine to allotransplantation. The most frequent extra-hematologic toxicity was peripheral neuropathy, observed in 21.5% of cases (9 patients with grade 1/2 and 5 patients with grade 3/4); neurological toxicity led to discontinuation of treatment in three patients and to dose reduction in four. In general the treatment was well tolerated and toxicities, both hematologic and extra-hematologic, were manageable. This report indicates and confirms that brentuximab vedotin as a single agent is effective and safe also when used in standard, everyday clinical practice outside a clinical trial. Best overall responses were recorded after three or four cycles and showed that brentuximab vedotin provides an effective bridge to further therapeutic interventions.

AB - Clinical trial results indicate that brentuximab vedotin brings considerable promise for the treatment of patients with relapsed or refractory Hodgkin's lymphoma. A retrospective multicenter study was conducted on 65 heavily pretreated patients who underwent therapy through a Named Patient Program in Italy (non trial-setting). The primary study endpoint was the objective response rate; secondary endpoints were safety, overall survival and progression- free survival. The best overall response rate (70.7%), including 21.5% complete responses, was observed at the first restaging after the third cycle of treatment. After a median follow up of 13.2 months, the overall survival rate at 20 months was 73.8% while the progression-free survival rate at 20 months was 24.2%. Globally nine patients are in continuous complete response with a median follow up of 14 months (range, 10-19 months). Four patients proceeded to autotransplantation and nine to allotransplantation. The most frequent extra-hematologic toxicity was peripheral neuropathy, observed in 21.5% of cases (9 patients with grade 1/2 and 5 patients with grade 3/4); neurological toxicity led to discontinuation of treatment in three patients and to dose reduction in four. In general the treatment was well tolerated and toxicities, both hematologic and extra-hematologic, were manageable. This report indicates and confirms that brentuximab vedotin as a single agent is effective and safe also when used in standard, everyday clinical practice outside a clinical trial. Best overall responses were recorded after three or four cycles and showed that brentuximab vedotin provides an effective bridge to further therapeutic interventions.

UR - http://www.scopus.com/inward/record.url?scp=84880975413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880975413&partnerID=8YFLogxK

U2 - 10.3324/haematol.2012.083048

DO - 10.3324/haematol.2012.083048

M3 - Article

VL - 98

SP - 1232

EP - 1236

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -